200,000+ products from a single source!
sales@angenechem.com
181816-48-8 | Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]-, (2S)-
CAS No: 181816-48-8 Catalog No: AG00233U MDL No:MFCD00951209
Product Description
Catalog Number:
AG00233U
Chemical Name:
Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]-, (2S)-
CAS Number:
181816-48-8
Molecular Formula:
C21H26N2O6
Molecular Weight:
402.4409
MDL Number:
MFCD00951209
IUPAC Name:
(2S)-2-amino-3-hydroxy-N-[2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide
InChI:
InChI=1S/C21H26N2O6/c1-26-17-8-7-13(9-16(17)23-21(25)15(22)12-24)5-6-14-10-18(27-2)20(29-4)19(11-14)28-3/h5-11,15,24H,12,22H2,1-4H3,(H,23,25)/b6-5-/t15-/m0/s1
InChI Key:
IXWNTLSTOZFSCM-YVACAVLKSA-N
SMILES:
OC[C@@H](C(=O)Nc1cc(/C=C\c2cc(OC)c(c(c2)OC)OC)ccc1OC)N
UNII:
82JB1524Q6
Properties
Complexity:
517
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
1
Defined Bond Stereocenter Count:
1
Exact Mass:
402.179g/mol
Formal Charge:
0
Heavy Atom Count:
29
Hydrogen Bond Acceptor Count:
7
Hydrogen Bond Donor Count:
3
Isotope Atom Count:
0
Molecular Weight:
402.447g/mol
Monoisotopic Mass:
402.179g/mol
Rotatable Bond Count:
9
Topological Polar Surface Area:
112A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.2
Literature
| Title | Journal |
|---|---|
| Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic. | Current drug targets 20111201 |
| Cardiovascular toxicity profiles of vascular-disrupting agents. | The oncologist 20110801 |
| Contrast ultrasonography: necessity of linear data processing for the quantification of tumor vascularization. | Ultraschall in der Medizin (Stuttgart, Germany : 1980) 20100801 |
| [Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents]. | Yao xue xue bao = Acta pharmaceutica Sinica 20100301 |
| Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs. | Bioorganic & medicinal chemistry letters 20091215 |
| AVE8062: a new combretastatin derivative vascular disrupting agent. | Expert opinion on investigational drugs 20091001 |
| Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth. | Cancer science 20080701 |
| Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. | Cancer research 20071001 |
| Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700). | Chemotherapy 20051001 |
| Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700). | British journal of cancer 20040126 |
| Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. | British journal of cancer 20031006 |
| Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. | Cancer science 20030201 |
| Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer. | International journal of clinical oncology 20020601 |
| A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. | British journal of cancer 20020520 |
| Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. | Medical science monitor : international medical journal of experimental and clinical research 20010101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.